share_log

BRIEF-TG Therapeutics Completes Rolling Submission Of Biologics License Application To The U.S. Food And Drug Administration

路透社 ·  Mar 29, 2021 20:13
March 29 (Reuters) - TG Therapeutics Inc :
   * TG THERAPEUTICS COMPLETES ROLLING SUBMISSION OF BIOLOGICS LICENSE APPLICATION TO THE U.S. FOOD AND DRUG ADMINISTRATION FOR UBLITUXIMAB IN COMBINATION WITH UKONIQ™(UMBRALISIB) AS A TREATMENT FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
   * TG THERAPEUTICS COMPLETES ROLLING SUBMISSION OF BIOLOGICS LICENSE APPLICATION TO THE U.S. FOOD AND DRUG ADMINISTRATION FOR UBLITUXIMAB IN COMBINATION WITH UKONIQ™(UMBRALISIB) AS A TREATMENT FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

Source text for Eikon:  Further company coverage:

((Reuters.Briefs@thomsonreuters.com;)
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment